Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.

Sevenum, the Netherlands, 3 October 2024. The Management Board of Redcare Pharmacy has decided to intensify marketing investments for its e-Rx business in Germany in Q4 based on very convincing metrics, specifically the repeat order rate and average basket size. This decision is driven by the firm belief that the right investments now will result in further profitable growth and expansion of Redcare Pharmacy’s market leadership.

The Management Board of Redcare Pharmacy has updated the full-year guidance for 2024 as follows:

• Total Group sales of EUR 2.35 to EUR 2.5 billion (previously, EUR 2.3 to EUR 2.5 billion).
• Non-Rx sales growth of 20-25% (previously 15-25%).
• MediService sales to grow by lower half of single digits (previously mid-single digits).
• Adjusted EBITDA margin of 1.2-2.2% (previously 2-4%).
• Rx too dynamic to give guidance (unchanged).